Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
Date:6/5/2008

NEW YORK, June 5 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). The full 56-page report can be found at http://www.crystalra.com .

Arana Therapeutics Ltd. ("Arana" or "the Company") is a biotechnology company developing next-generation antibody therapeutics to treat inflammatory diseases and cancer. Arana's business is divided into two sectors: (1) protein engineering technologies; and (2) therapeutics development. The Company's technology platform includes its Superhumanisation(TM), Synhumanisation(R), and EvoGene(TM) proprietary processes. Application of these technologies can transform lead proteins, including antibodies, into safe, potent therapeutic candidates. The resulting products may be less immunogenic (less likely to cause side effects) yet retain the crucial binding properties of the starting antibody.

At present, the Company licenses its protein engineering platform to CSL Ltd. (CSL-ASX), GlaxoSmithKline plc (GSK-NYSE), Aveo Pharmaceuticals, Inc., and Vegenics Ltd. Additionally, Arana can use its technologies to decrease the timeline and minimize the financial risks of its therapeutic antibody development. The Company does this by further enhancing already validated targets that would otherwise be excluded from development due to existing competitor patents.

Arana's product pipeline consists of eight candidates targeting inflammatory diseases as well as bone, lung, and colorectal cancer, melanoma, leukemia, and solid tumors. ART621, the Company's most advanced candidate, is a Tumor Necrosis Factor alpha (TNF alpha)-blocker for rheumatoid arthritis (RA), psoriasis, and Crohn's disease. In March 2008, the Company commenced Phase II clinical trials of ART621 in psoriasis patients. Within Arana's Cancer Franchise, the lead product candidate is ART010, an engineered version of a naturally occurring protein being developed for treating cancer related to bone disease and osteoporosis. Arana expects to begin manufacturing ART010 in 2008 and could enter Phase I trials in late 2009. Arana has headquarters in Sydney, Australia, with facilities in Melbourne, Australia, and San Francisco, California.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
2. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
3. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. Researchers outline structure of largest nonvirus particle ever crystallized
6. 3-D photonic crystals will revolutionize telecommunications
7. Recombinant Human Renin - Crystallographic Grade
8. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
9. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North Carolina, ... Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring ... kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):